As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers.

The MRFR report includes a thorough assessment of the global immune thrombocytopenia (ITP) market along with a five-year (2018-2023) revenue forecast. The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes. A detail analysis of the various sub-markets across key region of the world is also available in the report.

Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market

Competitive Landscape:

CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.

Research Methodology:

The research methodology envelops the range and depth of markets and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.

Segmental Analysis:

The segmental analysis of the global ITP market is based on type, treatment, end-user and region. By type, the market has been segmented into chronic immune thrombocytopenia and acute immune thrombocytopenia. In 2017, the chronic immune thrombocytopenia segment for 85% share of the global market. During the forecast period, the segment is projected to witness a CAGR of 5.94% and reach a valuation of USD 2,036.9 Mn. This can be attributed to factors such as rising incidence rates, approval of targeted treatments, increase in risk factors, use of prior medications, and increase occurrence of secondary hematological disorders.

On the basis of the treatment, the market has been segmented into intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others. In 2017, the corticosteroids segmented represented 40% share of the global ITP market in terms of value. The segment is likely to surge at a CAGR of 5.57% during the assessment period. Corticosteroids are a class of steroid hormones that are commonly used in ITP therapies.

On the basis of end-user, the market has been segmented into hospitals and clinics, specialty centers, research and academic institutes, and others. The hospitals & clinic segment currently commands for close to 38% market share and is projected to capture an impressive CAGR of 6.22% during the review period.

Regional Outlook:

On the basis of region, the Global ITP market is segmented into Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, the Americas accounted for 43.3% market share in 2017. The Americas is expected to spearhead the global ITP market throughout the assessment period. This is primarily owing to the increasing prevalence rates coupled with the availability of treatment options and presence effective reimbursement policies. According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In addition, Americas is expected to remain an important market for ITP during the assessment period. Americas is followed by Europe and Asia-Pacific respectively. In Europe, factors such as favorable government policies and high healthcare expenditure is supporting the growth of the market. At the same time, presence of advanced healthcare infrastructure is providing an impetus to the market in Europe. The region is likely to remain its second spot over 2023. In Asia Pacific, increased efforts towards improving healthcare services and rising level of awareness among people is anticipated to drive the market’s growth in APAC in the forthcoming years.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/immune-thrombocytopenia-itp-market-6996

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]